Nothing Special   »   [go: up one dir, main page]

Fontana et al., 2005 - Google Patents

Fibronectin is required for integrin o: vβ6‐mediated activation of latent TGF‐β complexes containing LTBP‐1

Fontana et al., 2005

View PDF @Full View
Document ID
16440042424012865410
Author
Fontana L
Chen Y
Prijatelj P
Sakai T
Fässler R
Sakai L
Rifkin D
Publication year
Publication venue
The FASEB journal

External Links

Snippet

Transforming growth factor‐βs (TGF‐β) are secreted as latent complexes consisting of the TGF‐β dimer, the TGF‐β propeptide dimer, and the latent TGF‐β binding protein (LTBP). Although the bonds between TGF‐β and its propeptide are cleaved intracellulary, the …
Continue reading at faseb.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin

Similar Documents

Publication Publication Date Title
Fontana et al. Fibronectin is required for integrin o: vβ6‐mediated activation of latent TGF‐β complexes containing LTBP‐1
Thomas et al. The role of the Angiopoietins in vascular morphogenesis
Lau CCN1/CYR61: the very model of a modern matricellular protein
Rodgers et al. Cellular interactions with elastin
Jun et al. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets
Preissner et al. Vitronectin in vascular context: facets of a multitalented matricellular protein
Asano et al. Increased expression of integrin αvβ5 induces the myofibroblastic differentiation of dermal fibroblasts
Chen et al. Functions and mechanisms of action of CCN matricellular proteins
Kurundkar et al. The matricellular protein CCN1 enhances TGF-β1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury
Roth et al. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair
Fan et al. Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro
Chavakis et al. Regulation of neovascularization by human neutrophil peptides (α‐defensins): a link between inflammation and angiogenesis
Horowitz et al. Plasminogen activation–induced pericellular fibronectin proteolysis promotes fibroblast apoptosis
Nyberg et al. Endogenous inhibitors of angiogenesis
Masckauchán et al. Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2
Munger et al. Interactions between growth factors and integrins: latent forms of transforming growth factor-β are ligands for the integrin αvβ1
Asano et al. Increased expression levels of integrin αvβ5 on scleroderma fibroblasts
Nyberg et al. Characterization of the anti-angiogenic properties of arresten, an α1β1 integrin-dependent collagen-derived tumor suppressor
Li et al. Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease
Quax et al. Adenoviral expression of a urokinase receptor–targeted protease inhibitor inhibits neointima formation in murine and human blood vessels
US20020159986A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US7534572B2 (en) Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
Carpizo et al. Endogenous regulators of angiogenesis–emphasis on proteins with thrombospondin–type I motifs
Mukherjee et al. Insulin-like growth factor (IGF) binding protein-5 blocks skeletal muscle differentiation by inhibiting IGF actions
Zhou et al. Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis